Subscribe To
MAIA / MAIA Biotechnology (MAIA) Up on Positive Data From NSCLC Study
MAIA News
By Business Wire
October 19, 2023
MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at ESMO Congress 202 more_horizontal
By Seeking Alpha
July 1, 2023
MAIA Biotechnology: Progress In The THIO-101 Trial Sets Up A 2023 Catalyst
MAIA's THIO-101 trial of 6-thio-2-deoxyguanosine in non-small cell lung cancer had enrolled 29 patients as of a June 20 update from the company. The f more_horizontal
By Zacks Investment Research
April 12, 2023
MAIA Biotechnology (MAIA) Up on Positive Data From NSCLC Study
MAIA Biotechnology (MAIA) gains on encouraging data on lead candidate from Part A of its mid-stage study in advanced non-small cell lung cancer. more_horizontal